Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Overview of attention for article published in Blood, November 2018
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (83rd percentile)
-
Good Attention Score compared to outputs of the same age and source (79th percentile)
Readers on
- mendeley
- 32 Mendeley